RxDoctor Payments Data

Cole Lundquist, MD

Dermatology · Park Ridge, ILNPI 1982688891

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $46,920 of the $68,689 with a category attached, or 68.3%. Bristol Myers Squibb accounts for 70.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $56,669 and has fallen 91.6% since, to $4,750 in 2025. Among dermatology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$68,689in general payments, 2019–2025

Across 181 payments — averaging $379.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$48K
  • EPI Health, LLC$7K
  • Amgen$6K
  • Journey Medical Corporation$5K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$489
  • Dermavant Sciences, Inc.$459
  • plus $618 from 10 others

What the payments were for

  • Consulting fees$10,28515%
  • Speaking & faculty fees$46,92068%
  • Travel & lodging$7,36711%
  • Food & beverage$4,0326%
  • Education$850%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,689 in reported general payments places this provider in the 90th percentile of 606 dermatology providers in Illinois.

See all dermatology providers in Illinois

Medicare billing

Part B allowed, 2024
$680,892
Medicare patients
534
Services billed
6,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab11$143,046
RinvoqUpadacitinib15$95,993
Dupixent PenDupilumab25$92,405
VtamaTapinarof29$40,220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$40$95,99315 claims
Dermavant Sciences, Inc.Vtama$459$40,22029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 606 dermatology providers in Illinois.

Other dermatology in Park Ridge

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →